News Release Details
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
"I am delighted to welcome John to Phio. John is a seasoned and passionate leader who brings a wealth of experience developing immuno-oncology gene and cell therapies," said Dr.
Dr. Barrett has accumulated over 25 years of experience working in research and development and is an expert in developing cell-based immuno-oncology therapies - such as developing intratumoral therapeutics that control gene expression levels to turn cold tumors hot, as well as CAR T-cells and TCRs. Prior to joining Phio, Dr. Barrett spent 8 years at
About Phio Pharmaceuticals Corp.
NASDAQ Rule 5653(c)(4) Notice
As an inducement to join the Company, Dr. Barrett was granted a Restricted Stock Unit representing the right to receive 222,991 shares of common stock (the "Inducement Award"). The Inducement Award vests over a four-year period from the date of grant. The Inducement Award was granted outside of the Company's shareholder-approved equity compensation plans, but will be governed in all respects as if granted under the Company's 2012 Long Term Incentive Plan.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, expected duration of available cash runway, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.